We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Orphazyme (ORPH) Up on Plans of NDA Resubmission for Rare Drug
Read MoreHide Full Article
Denmark-based biopharmaceutical company, Orphazyme A/S announced an update on the timeline of its planned resubmission of the new drug application (“NDA”) for its investigational product candidate, arimoclomol, for the treatment of Niemann-Pick disease type C (“NPC”), a rare genetic disorder. Currently, there are no approved treatments for the given indication in the United States.
The company is planning to request a Type C Meeting with the FDA in the second quarter of 2022. Subject to discussions with the regulatory body, Orphazyme plans to resubmit the NDA for arimoclomol in the second half of 2022.
Shares of Orphazyme were up 8.3% on Friday following the announcement of the news. However, the stock has plunged 82.1% in the past year compared with the industry’s decrease of 40.4%.
Image Source: Zacks Investment Research
In June 2021, the FDA issued a Complete Response Letter (“CRL”) to the NDA for arimoclomol for the treatment of NPC. The company had a Type A Meeting with the FDA in October 2021, wherein the regulatory body requested additional data, information and analyses on certain topics of the CRL.
In line with recommendations from the regulatory body during the Type A Meeting, the company is looking to request a Type C Meeting to discuss the additional data, information and analyses related to certain topics mentioned in the CRL.
In November 2020, Orphazyme filed a marketing authorization application seeking approval for arimoclomol for the treatment NPC to the European Medicines Agency ("EMA"). An opinion from the EMA’s Committee for Medicinal Products for Human Use is expected later in the first quarter of 2022.
The FDA has already granted Fast-Track Designation, Breakthrough Therapy Designation and Rare Pediatric Disease Designation to arimoclomol for treating NPC. The candidate has received Orphan Drug Designation for addressing NPC both in the United States and Europe.
Successful development of arimoclomol remains a primary focus for the company.
Image: Bigstock
Orphazyme (ORPH) Up on Plans of NDA Resubmission for Rare Drug
Denmark-based biopharmaceutical company, Orphazyme A/S announced an update on the timeline of its planned resubmission of the new drug application (“NDA”) for its investigational product candidate, arimoclomol, for the treatment of Niemann-Pick disease type C (“NPC”), a rare genetic disorder. Currently, there are no approved treatments for the given indication in the United States.
The company is planning to request a Type C Meeting with the FDA in the second quarter of 2022. Subject to discussions with the regulatory body, Orphazyme plans to resubmit the NDA for arimoclomol in the second half of 2022.
Shares of Orphazyme were up 8.3% on Friday following the announcement of the news. However, the stock has plunged 82.1% in the past year compared with the industry’s decrease of 40.4%.
In June 2021, the FDA issued a Complete Response Letter (“CRL”) to the NDA for arimoclomol for the treatment of NPC. The company had a Type A Meeting with the FDA in October 2021, wherein the regulatory body requested additional data, information and analyses on certain topics of the CRL.
In line with recommendations from the regulatory body during the Type A Meeting, the company is looking to request a Type C Meeting to discuss the additional data, information and analyses related to certain topics mentioned in the CRL.
In November 2020, Orphazyme filed a marketing authorization application seeking approval for arimoclomol for the treatment NPC to the European Medicines Agency ("EMA"). An opinion from the EMA’s Committee for Medicinal Products for Human Use is expected later in the first quarter of 2022.
The FDA has already granted Fast-Track Designation, Breakthrough Therapy Designation and Rare Pediatric Disease Designation to arimoclomol for treating NPC. The candidate has received Orphan Drug Designation for addressing NPC both in the United States and Europe.
Successful development of arimoclomol remains a primary focus for the company.
Zacks Rank & Stocks to Consider
Orphazyme currently carries a Zacks Rank #3 (Hold). Better-ranked stocks in the biotech sector include Axsome Therapeutics, Inc. (AXSM - Free Report) , Editas Medicine, Inc. (EDIT - Free Report) and Kaleido Biosciences, Inc. , all sporting a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Axsome Therapeutics’ loss per share estimates have narrowed 0.8% for 2022 over the past 60 days.
Earnings of Axsome Therapeutics have surpassed estimates in three of the trailing four quarters and missed the same on the other occasion.
Editas Medicine’s loss per share estimates have narrowed 1.4% for 2022 over the past 60 days.
Earnings of Editas Medicine have surpassed estimates in two of the trailing four quarters and missed the same on the other two occasions.
Kaleido Biosciences’ loss per share estimates have narrowed 11.3% for 2022 over the past 60 days.
Earnings of Kaleido Biosciences have surpassed estimates in three of the trailing four quarters and missed the same on the other occasion.